Open    Access



Metabolic and Anthropometric Effects of NADH RAPID ENERGY® in Diabetic Type 2



Author(s)

Rahal Lotfi¹, Joerg George Birkmayer² and Ahmed Ghouini¹

Full-Text PDF XML     924 Views

DOI:10.17265/2159-5828/2016.05.005

1. University Hospital of Blida, Faculty of Medicine, Blida 09000, Algeria 2. Dept. of Medical Chemistry, University of Graz, Graz 8020, Austria

Twenty patients with diabetes type-2, aged between 38 and 61 years, with at least one cardiovascular risk factor were divided in two groups (Group-1 included newly diagnosed type 2 diabetic patients without treatment with oral antidiabetic OAD, Group-2: patients with diabetes type 2 under OAD +/- insulin (N = 11)). Patients from both groupswere taking Nicotinamide Adenine Dinucleotide (NADH) Rapid Energy® 80 mg/day in two takes for a period of 56 days. A greater reduction in average fasting glucose and HbA1c after 56 days was observed in the patients of group 1 not taking metformin compared to patients of group-2 which were taking metformin. Why metformin reduces the anti-diabetic effect of NADH will be discussed.

NADH, Coenzmye-1, diabetes, type 2, metabolic profile, anthropometry, mitochondrial diseases.